Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up-Reference-Cited by-同舟云学术

Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

Published:2015-05 Issue:5 Volume:39 Page:520-524
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Cabrero Monica,Jabbour Elias,Ravandi Farhad,Bohannan Zach,Pierce Sherry,Kantarjian Hagop M.,Garcia-Manero Guillermo

Funder

Fundacion Alfonso Martin-Escudero

Edward P. Evans Foundation

Fundacion Ramon Areces

Cancer Prevention & Research Institute of Texas (CPRIT)

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference17 articles.

1. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

2. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies;Issa;Blood,2004

3. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

4. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia;Kantarjian;J Clin Oncol,2012

5. Hypomethylating agents and other novel strategies in myelodysplastic syndromes;Garcia-Manero;J Clin Oncol,2011

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09

2. Real‐world study of the use of azacitidine in myelodysplasia in Australia;eJHaem;2024-05-17

3. Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study;The Lancet Haematology;2024-01

4. Research Progress of Decitabine in Myelodysplastic Syndromes;Advances in Clinical Medicine;2024

5. Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices;Leukemia & Lymphoma;2023-09-07